132 related articles for article (PubMed ID: 22945814)
1. [New drug treatment possibilities in castration resistant prostate carcinoma].
Meisel A; Stenner F
Praxis (Bern 1994); 2012 Sep; 101(18):1143-9; quiz 1150-1. PubMed ID: 22945814
[No Abstract] [Full Text] [Related]
2. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Kim W; Ryan CJ
Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; George DJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
7. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
Attard G; de Bono JS
Clin Cancer Res; 2011 Jun; 17(12):3867-75. PubMed ID: 21680542
[TBL] [Abstract][Full Text] [Related]
8. New strategies for medical management of castration-resistant prostate cancer.
Asmane I; Céraline J; Duclos B; Rob L; Litique V; Barthélémy P; Bergerat JP; Dufour P; Kurtz JE
Oncology; 2011; 80(1-2):1-11. PubMed ID: 21577012
[TBL] [Abstract][Full Text] [Related]
9. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
10. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
11. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
12. [Palliative systemic therapy of castration-resistant prostate cancer: current developments].
Finter F; Rinnab L; Gust K; Küfer R
Urologe A; 2009 Nov; 48(11):1295-301. PubMed ID: 19847385
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
14. Advanced clinical states in prostate cancer.
Cheng HH; Lin DW; Yu EY
Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
[TBL] [Abstract][Full Text] [Related]
15. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Harrington JA; Jones RJ
Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
[TBL] [Abstract][Full Text] [Related]
16. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Li J; Armstrong AJ
Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
[No Abstract] [Full Text] [Related]
17. Novel options for the treatment of castration-resistant prostate cancer.
Ohlmann CH; Merseburger AS; Suttmann H; Schilling D; Trojan L; Kempkensteffen C; Corvin S; Mathers MJ; Bastian PJ
World J Urol; 2012 Aug; 30(4):495-503. PubMed ID: 22101903
[TBL] [Abstract][Full Text] [Related]
18. Castration-refractory prostate cancer: new therapies, new questions.
Appleman LJ
Oncology (Williston Park); 2010 Dec; 24(14):1318-9, 1326. PubMed ID: 21294476
[No Abstract] [Full Text] [Related]
19. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
20. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Miki T; Okihara K
Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
[No Abstract] [Full Text] [Related]
[Next] [New Search]